Carregant...
FLT3 inhibitors in acute myeloid leukemia
FLT3 mutations are one of the most common findings in acute myeloid leukemia (AML). FLT3 inhibitors have been in active clinical development. Midostaurin as the first-in-class FLT3 inhibitor has been approved for treatment of patients with FLT3-mutated AML. In this review, we summarized the preclini...
Guardat en:
| Publicat a: | J Hematol Oncol |
|---|---|
| Autors principals: | , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
BioMed Central
2018
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6280371/ https://ncbi.nlm.nih.gov/pubmed/30514344 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-018-0675-4 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|